Paul Hudson (AP Images)

Sanofi CEO Paul Hud­son’s lat­est M&A gam­bit adds new eczema drug in $1.5B buy­out. And he’s steer­ing back in­to a mar­ket mael­strom

Around the same time that Sanofi CEO Paul Hud­son was en­gi­neer­ing a $3.7 bil­lion buy­out of Prin­cip­ia to add a late-stage mul­ti­ple scle­ro­sis drug to the pipeline last Au­gust, the team at Kymab was post­ing up­beat re­marks about its mid-stage da­ta on their ri­val OX40L drug for atopic der­mati­tis. Now Hud­son has come back in to ink a $1.45 bil­lion deal to buy Kymab out and add that to the late-stage im­muno-in­flam­ma­tion pipeline as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.